Predict your next investment

Plum Alley company logo
Venture Capital
FINANCE | Investment Firms & Funds
plumalley.co

See what CB Insights has to offer

Investments

25

Portfolio Exits

1

About Plum Alley

Plum Alley Investments is a venture firm investing in early-stage, high-growth technology and healthcare companies with at least one woman founder from the STEM fields. Plum Alley invests in advanced technologies and medical breakthroughs disrupting huge markets and driving exponential value for people, the planet, markets, and the economy.

Plum Alley Headquarter Location

43 West 23rd Street

New York, New York, 10010,

United States

347-348-7901

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Plum Alley

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Plum Alley in 1 Expert Collection, including E-Commerce.

E

E-Commerce

9,499 items

Plum Alley Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Plum Alley Rank

Latest Plum Alley News

Ashvattha Therapeutics Announces $69 Million in Series B

Apr 28, 2022

Redwood City, UNITED STATES – Series B Financing led by Huadong Medicine Investment Holding Co., Ltd, with participation from Natural Capital Investment Fund, Plum Alley Investments and Tribe Capital – – Exclusive product licensing agreement grants Huadong development and commercialization rights to Ashvattha pipeline assets in Asia – – Ashvattha’s hydroxyl dendrimer-based precision medicine pipeline includes clinical stage candidates for severe COVID-19, wet AMD/DME and ALS with significant milestones expected in 2022 – REDWOOD CITY, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced it has secured $69 million in a Series B financing and in a separate agreement entered an exclusive licensing deal with Huadong Medicine. Proceeds will support the advancement of Ashvattha’s pipeline of hydroxyl dendrimer therapeutics (HDTs), including multiple clinical stage programs. Ashvattha launched a Phase 2 study in severe COVID-19 earlier this year and in 2022 plans to launch a Phase 2 study in wet AMD/DME and Phase 1/2 study in ALS. The Series B financing was led by Huadong Medicine Investment Holding Co., Ltd, with participation from existing investors, including Natural Capital, Plum Alley, Tribe Capital and several prominent technology and biotech angel investors bringing Ashvattha’s total funding to $69 million. The exclusive licensing agreement with Huadong which includes up to $45 million advanced payments for product development, grants Huadong development and commercialization rights to its pipeline assets in China and parts of southeast Asia. Under the terms of the exclusive licensing agreement: Huadong will advance up to $30 million to cover research and development costs for Ashvattha’s hydroxyl dendrimer clinical candidates, OP-101, D-4517.2 and OP-801, and $15 million for additional preclinical candidates Huadong will gain exclusive licensing rights to develop, manufacture and commercialize these candidates in China, and southeast Asian countries such as Singapore and Malaysia. Huadong will pay Ashvattha a royalty of 10% of net sales of licensed products HDTs have been shown to selectively target reactive inflammatory cells in diseased tissue, with the ability to cross the blood-brain barrier and blood-retinal barrier to treat neurology, ophthalmology, and inflammatory diseases. Interim data from ongoing Phase 2 PRANA clinical study in severe COVID-19 patients demonstrated the ability of OP-101, an HDT, to cross the blood-brain barrier and reduce neuronal injury and systemic hyperinflammation, reinforcing the potential of the HD platform. “We believe that hydroxyl dendrimer therapeutics are the future of precision medicine and look forward to demonstrating this with multiple clinical data catalysts in our ophthalmology, neurology and inflammatory programs this year,” said Jeffrey Cleland, Ph.D., Chairman & CEO of Ashvattha Therapeutics. “This investment and partnership confirm confidence in our approach to precision medicine with disease-cell selective HDTs, as well as the broad potential of our platform, and the potential to dramatically increase the therapeutic index of drugs.” Mr. Lv Liang, Chairman of Huadong Medicine, added, “We believe Ashvattha’s hydroxyl dendrimer platform has the potential to produce highly selective drugs. This collaboration will enable us to build an R&D ecosystem, further enriching our pipeline in the fields of tumor, immunity and endocrinology. This allows us to accelerate scientific research innovation and internationalization. We look forward to working with Ashvattha to advance a new class of therapeutics that may hold the potential to enhance the treatment landscape for a broad range of patient populations.” About OP-101 OP-101 is an HDT with N-acetyl cysteine (NAC) that selectively targets reactive macrophages and microglia, which are responsible for hyperinflammation, lung injury and multi-organ failure caused by viral or bacterial infections, including COVID-19. About D-4517.2 D-4517.2 is an HDT with potent anti-angiogenic activity inhibiting VEGFR/PDGFR that selectively targets reactive inflammatory cells and crosses the blood-retinal barrier. About OP-801 OP-801 is an HD imaging agent that provides information on uptake of HDs across tissue barriers including the blood brain barrier. 18F-OP-801 selectively targets reactive microglia in regions of neuroinflammation in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. About Ashvattha Therapeutics Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology. The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University. HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects. Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), and hyperinflammation in diseases such as COVID-19. For more information, visit: www.avttx.com . Media Contact

Plum Alley Investments

25 Investments

Plum Alley has made 25 investments. Their latest investment was in Ashvattha Therapeutics as part of their Series B on April 4, 2022.

CBI Logo

Plum Alley Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/28/2022

Series B

Ashvattha Therapeutics

$69M

Yes

1

1/10/2022

Series A

Gameto

$20M

Yes

23

11/19/2021

Series A

Helaina

$20M

Yes

14

9/9/2021

Series D

Subscribe to see more

$99M

Subscribe to see more

10

8/6/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/28/2022

1/10/2022

11/19/2021

9/9/2021

8/6/2021

Round

Series B

Series A

Series A

Series D

Series A

Company

Ashvattha Therapeutics

Gameto

Helaina

Subscribe to see more

Subscribe to see more

Amount

$69M

$20M

$20M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

23

14

10

10

Plum Alley Portfolio Exits

1 Portfolio Exit

Plum Alley has 1 portfolio exit. Their latest portfolio exit was Node on August 24, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/24/2020

Acquired

$99M

13

Date

8/24/2020

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

13

Plum Alley Team

3 Team Members

Plum Alley has 3 team members, including current Founder, Chief Executive Officer, Deborah B Jackson.

Name

Work History

Title

Status

Deborah B Jackson

Shattuck Hammond Partners, and Goldman Sachs

Founder, Chief Executive Officer

Current

Andrea Turner Moffitt

Founder

Current

Avantika Daing

Managing Director

Current

Name

Deborah B Jackson

Andrea Turner Moffitt

Avantika Daing

Work History

Shattuck Hammond Partners, and Goldman Sachs

Title

Founder, Chief Executive Officer

Founder

Managing Director

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.